Role of active metabolites in the use of opioids - PubMed

Review

Role of active metabolites in the use of opioids

Janet K Coller et al. Eur J Clin Pharmacol. 2009 Feb.

Abstract

The opioid class of drugs, a large group, is mainly used for the treatment of acute and chronic persistent pain. All are eliminated from the body via metabolism involving principally CYP3A4 and the highly polymorphic CYP2D6, which markedly affects the drug's function, and by conjugation reactions mainly by UGT2B7. In many cases, the resultant metabolites have the same pharmacological activity as the parent opioid; however in many cases, plasma metabolite concentrations are too low to make a meaningful contribution to the overall clinical effects of the parent drug. These metabolites are invariably more water soluble and require renal clearance as an important overall elimination pathway. Such metabolites have the potential to accumulate in the elderly and in those with declining renal function with resultant accumulation to a much greater extent than the parent opioid. The best known example is the accumulation of morphine-6-glucuronide from morphine. Some opioids have active metabolites but at different target sites. These are norpethidine, a neurotoxic agent, and nordextropropoxyphene, a cardiotoxic agent. Clinicians need to be aware that many opioids have active metabolites that will become therapeutically important, for example in cases of altered pathology, drug interactions and genetic polymorphisms of drug-metabolizing enzymes. Thus, dose individualisation and the avoidance of adverse effects of opioids due to the accumulation of active metabolites or lack of formation of active metabolites are important considerations when opioids are used.

Similar articles

• Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

  Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Pergolizzi J, et al. Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626

• Pharmacogenetics of opioids.

  Somogyi AA, Barratt DT, Coller JK. Somogyi AA, et al. Clin Pharmacol Ther. 2007 Mar;81(3):429-44. doi: 10.1038/sj.clpt.6100095. Clin Pharmacol Ther. 2007. PMID: 17339873 Review.

• Distinct pharmacological properties of morphine metabolites at G(i)-protein and β-arrestin signaling pathways activated by the human μ-opioid receptor.

  Frölich N, Dees C, Paetz C, Ren X, Lohse MJ, Nikolaev VO, Zenk MH. Frölich N, et al. Biochem Pharmacol. 2011 May 15;81(10):1248-54. doi: 10.1016/j.bcp.2011.03.001. Epub 2011 Mar 17. Biochem Pharmacol. 2011. PMID: 21396918

• The metabolism of opioid agents and the clinical impact of their active metabolites.

  Smith HS. Smith HS. Clin J Pain. 2011 Nov-Dec;27(9):824-38. doi: 10.1097/AJP.0b013e31821d8ac1. Clin J Pain. 2011. PMID: 21677572 Review.

• Opioid and adjuvant analgesics: compared and contrasted.

  Khan MI, Walsh D, Brito-Dellan N. Khan MI, et al. Am J Hosp Palliat Care. 2011 Aug;28(5):378-83. doi: 10.1177/1049909111410298. Epub 2011 May 26. Am J Hosp Palliat Care. 2011. PMID: 21622486 Review.

Cited by

• Differences between opioids: pharmacological, experimental, clinical and economical perspectives.

  Drewes AM, Jensen RD, Nielsen LM, Droney J, Christrup LL, Arendt-Nielsen L, Riley J, Dahan A. Drewes AM, et al. Br J Clin Pharmacol. 2013 Jan;75(1):60-78. doi: 10.1111/j.1365-2125.2012.04317.x. Br J Clin Pharmacol. 2013. PMID: 22554450 Free PMC article. Review.

• Toward a systematic approach to opioid rotation.

  Smith HS, Peppin JF. Smith HS, et al. J Pain Res. 2014 Oct 17;7:589-608. doi: 10.2147/JPR.S55782. eCollection 2014. J Pain Res. 2014. PMID: 25378948 Free PMC article. Review.

• The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.

  Kang JH, Oh SY, Song SY, Lee HY, Kim JH, Lee KE, Lee HR, Hwang IG, Park SH, Kim WS, Park YS, Park K. Kang JH, et al. Korean J Intern Med. 2015 Jan;30(1):88-95. doi: 10.3904/kjim.2015.30.1.88. Epub 2014 Dec 30. Korean J Intern Med. 2015. PMID: 25589840 Free PMC article.

• European Pain Federation position paper on appropriate opioid use in chronic pain management.

  O'Brien T, Christrup LL, Drewes AM, Fallon MT, Kress HG, McQuay HJ, Mikus G, Morlion BJ, Perez-Cajaraville J, Pogatzki-Zahn E, Varrassi G, Wells JC. O'Brien T, et al. Eur J Pain. 2017 Jan;21(1):3-19. doi: 10.1002/ejp.970. Eur J Pain. 2017. PMID: 27991730 Free PMC article.

• Predicting the efficacy of opioid sequestration by intravenous lipid emulsion using biologically relevant in vitro models of drug distribution.

  Tikhomirov M, Jajor P, Śniegocki T, Poźniak B. Tikhomirov M, et al. Sci Rep. 2022 Nov 4;12(1):18683. doi: 10.1038/s41598-022-21790-4. Sci Rep. 2022. PMID: 36333363 Free PMC article.

References

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer